Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer SAN CARLOS, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...

Cellectis Acquires Exclusive License to Tal Effector Patents From University of Minnesota PARIS, Jan. 20, 2011 (GLOBE NEWSWIRE) -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the...